This aligns with a recent report showing that the effect of the glutaminase inhibitor CB-839 on liver cancer can be further enhanced by several anti-metabolic drugs such as oxidative phosphorylation (OXPHOS) inhibitor IACS-10759, and G6PD inhibitor Dehydroepiandrosterone (DHEA) [69], which reinforces the idea that the unveiled dependence of G6PD expression on glutamine deprivation mediated by NRF2 pathway can open new avenues in the design of combined treatments to target glutamine addiction in colorectal cancer. Here, G6PD is linked to liver cancer.